Deals Surge, Returns Slip: Takeaways From a Record Half for Biotech IPOs

BioPharma Dive

"The boom for biotech initial public offerings that began early last decade reached an apex last year. Dozens of new companies flooded the marketplace and largely excelled, buoyed by a rising tide of enthusiasm in life sciences and the sector's role in containing the coronavirus pandemic. Previous records were smashed."

Read the article

Related Contacts
Charlie Kim Partner San Diego, Los Angeles